METTL1 and intrahepatic cholangiocarcinoma: Beyond HCC and ICC, OSCC exhibits METTL1‐driven tRNA m7G‐dependent metabolic reprogramming that promotes acquired resistance to anlotinib, whereas genetic or pharmacologic attenuation of METTL1 restores sensitivity, nominating an m7G‐translation‐metabolism axis as a tractable target.77